Articles

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, The Netherlands;Department of Hematology, University Medical Center Utrecht, The Netherlands;Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Genmab, Utrecht, The Netherlands
Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, The Netherlands;Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Research & Development, Innate Pharma, Marseille, France
Research & Development, Innate Pharma, Marseille, France
Department of Hematology, University Medical Center Utrecht, The Netherlands;Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Genmab, Utrecht, The Netherlands;Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, The Netherlands;Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Vol. 100 No. 2 (2015): February, 2015 https://doi.org/10.3324/haematol.2014.117531